FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought

FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31